Effacacy of compound glycyrrhizin in gemcitabine accociated rash and abnormal liver function: a randomized controlled, phase II study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-17012919

Enrollment

Unknown

Registered

2017-10-09

Start date

2018-01-01

Completion date

Unknown

Last updated

2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal cancer

Interventions

The trial group:compound glycyrrhizin injection

The control group:The same amount of normal saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cancer patients aged 18 to 70 years old, male and female; 2. Patients with hepatobiliary pancreatic cancer will be treated with the chemotherapy of gemcitabine; 3. There was no prior use of gemcitabine, immuno-modulator and glucocorticoids before treatment; 4. Subjects must understand and follow the drug dose and follow-up plan.

Exclusion criteria

Exclusion criteria: 1. Hepatic and renal insufficiency; 2. Pregnant or lactating women; 3. Abnormal immune functions; 4. Patients with low serum potassium; 5. Patients with Aldosterone; 6. Patients are known to be allergic to the Compound glycyrrhizin injection before; 7. Patients with severe uncontrollable diseases, acute infections and recent history of skin allergy; 8. The researchers found that other reasons were not suitable for the group.

Design outcomes

Primary

Measure	Time frame
size of skin rash;liver function indexes;	—

Countries

China

Contacts

Public ContactCao Dan

West China Hospital, Sichuan University

caodan316@163.com+86 18980605963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026